Grapiprant

Non-Steroidal Anti-Inflammatory Medication (Systemic Drug)

Prescriber Highlights

• Prostaglandin E₂ EP4-receptor antagonist (systemic drug), a new class of NSAID for treating osteoarthritis pain in dogs that does not inhibit cyclooxygenase (COX)

• Potentially causes fewer severe adverse effects in dogs than other NSAIDs

• GI effects (eg, vomiting, diarrhea) possible

Uses, Indications

• Approved for control of pain and inflammation associated with osteoarthritis in dogs

Contraindications, Warnings

• Contraindications

Patients with hypersensitivity to grapiprant or its components

• Warnings

  • Grapiprant has not been evaluated in dogs younger than 9 months of age or weighing less than 8 lbs (3.6 kgs)

  • Safe use has not been established in dogs used for breeding or in pregnant or lactating dogs

Side Effects

• GI distress (eg, vomiting; diarrhea; decreased appetite; mucoid, watery, or bloody stools)

• Decreased serum albumin and total protein

Drug Interactions

• Grapiprant is a substrate of P-glycoprotein transport, but no clinically relevant drug interactions have been identified

• No inhibition of metabolic pathways mediated by cytochrome P450 isoenzymes CYP1A2, CYP2C9, CYP2C19, CYP2D6, or CYP3A4

• Concurrent use with other anti-inflammatory drugs (eg, COX-inhibiting NSAIDs, corticosteroids) should be avoided

• Washout period suggested when switching from corticosteroids or COX-inhibiting NSAIDs to grapiprant

Monitoring

• Clinical efficacy, adverse events

• Appetite

• Emesis

• Stool characteristics

Client Information

• May be given with or without food; however, if vomiting occurs, give with food

• Most common adverse effects include vomiting, diarrhea, and decreased appetite

Dosage Forms

• Grapiprant flavored tablets: 20 mg, 60 mg, and 100 mg

‒Compiled and summarized from Plumb’s® Veterinary Drugs by Shannon Palermo, VMD